Want to see OSUR full AI Analyst Report?
Top Page
Orasure Technologies
(NASDAQ:OSUR)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.00
▲(0.76% Upside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by deteriorated TTM fundamentals—sharp revenue contraction, large losses, and significant cash burn. This is partially offset by a solid balance-sheet position discussed on the earnings call (strong cash, zero debt) and improving sequential trends with positive guidance, while technicals are broadly neutral and valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Strong liquidity and low leverage
A $161M cash balance with no debt gives OraSure multi-quarter runway to fund launches, absorb near-term cash burn, and invest in commercialization. Low leverage preserves strategic optionality and reduces refinancing risk while management prioritizes flexibility for product rollouts.
Negative Factors
Severe revenue and profit deterioration
A >50% TTM revenue decline and deeply negative margins materially reduce scale advantages and weaken returns. Persistent top-line shrinkage undermines long-term profitability and heightens the challenge of funding growth initiatives without structural recovery in demand or material cost restructuring.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong liquidity and low leverage
A $161M cash balance with no debt gives OraSure multi-quarter runway to fund launches, absorb near-term cash burn, and invest in commercialization. Low leverage preserves strategic optionality and reduces refinancing risk while management prioritizes flexibility for product rollouts.
Read all positive factors
Orasure Technologies (OSUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$278.84M
Dividend YieldN/A
Average Volume (3M)771.42K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth-30.08%
EPS Growth-143.79%
CountryUS
Employees501
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.69
Shares Outstanding68,848,560
10 Day Avg. Volume735,713
30 Day Avg. Volume771,421
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$120.50M
Orasure Technologies Business Overview & Revenue Model
Company Description
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States...
How the Company Makes Money
OraSure primarily makes money by selling diagnostic products and related components to distributors, healthcare providers, public health organizations, and other customers. Key revenue streams generally include: (1) sales of infectious disease dia...
Orasure Technologies Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call presents a cautiously positive picture: the company delivered sequential revenue growth (9.7%), segment recoveries (Diagnostics +14.7% and SMS +9.0% sequentially), margin expansion (+120 bps GAAP gross margin) and achieved important regulatory milestones (Colli‑Pee FDA clearance and Ebola 2.0 EUA). The primary setback is the withdrawal and delay of the IntelliQ CT/NG FDA submission, alongside a non‑GAAP operating loss ($14.7M) and negative operating cash flow (‑$9.9M) this quarter. Strong cash ($161M), zero debt, insourcing and cost discipline, and clear launch plans temper the impact of the IntelliQ delay and one‑time G&A items; management reiterates revenue growth for 2026 and expects operating cash flow breakeven entering 2027.Positive Updates
Revenue Growth and Guidance
Total revenue of $30.6M in Q2 2026, exceeding guidance and growing 9.7% sequentially; Q3 2026 revenue guidance of $29.5M–$32.5M.
Negative Updates
IntelliQ (CT/NG) Regulatory Delay
Company withdrew FDA submission for the IntelliQ CT/NG rapid molecular self‑test on the SHERLOQ platform after constructive FDA interactions; management no longer expects U.S. clearance and launch in 2026 and timing for resubmission/clearance is unconfirmed.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Guidance
Total revenue of $30.6M in Q2 2026, exceeding guidance and growing 9.7% sequentially; Q3 2026 revenue guidance of $29.5M–$32.5M.
Read all positive updates
Company Guidance
OraSure guided Q3 revenue of $29.5 million to $32.5 million with gross margin expected to be similar to Q2 (Q2 GAAP gross margin 43.5% and non‑GAAP gross margin 44.2%), reiterating full‑year 2026 revenue growth and a target of operating cash‑flow breakeven entering 2027; for context Q2 revenue was $30.6 million (up 9.7% sequentially) with Diagnostics $19.4 million (up 14.7% seq.) and SMS $9.9 million (up 9% seq.), Q2 operating cash flow was negative $9.9 million, GAAP operating income was $5.4 million (non‑GAAP operating loss $14.7 million), R&D was $9.4 million, S&M $6.6 million, G&A $14.4 million, non‑cash stock comp $2.3 million, D&A $2.4 million; balance sheet and capital notes included $161 million cash, zero debt, $2 million of share repurchases in Q2 (647k shares), $22 million returned year‑to‑date (7.7M shares, ~10% of shares; ~55% of a $40M authorization), a pause on buybacks to preserve flexibility for Colli‑Pee and Ebola 2.0 launch investments, an expected decline in G&A as nonrecurring items wind down, and a reduced contingent consideration liability tied to the IntelliQ resubmission plan.Orasure Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 112.41M | 115.02M | 185.83M | 405.47M | 387.48M | 233.67M |
| Gross Profit | 46.51M | 48.20M | 76.23M | 179.42M | 148.44M | 117.60M |
| EBITDA | -44.10M | -56.96M | -6.83M | 76.16M | -1.68M | 2.37M |
| Net Income | -49.13M | -68.73M | -19.50M | 53.66M | -17.13M | -23.00M |
Balance Sheet | ||||||
| Total Assets | 360.55K | 403.17M | 479.66M | 482.85M | 444.18M | 460.99M |
| Cash, Cash Equivalents and Short-Term Investments | 160.58K | 199.28M | 267.76M | 290.41M | 110.85M | 153.04M |
| Total Debt | 0.00 | 13.20M | 14.60M | 13.50M | 12.55M | 12.27M |
| Total Liabilities | 0.00 | 62.34M | 69.32M | 52.17M | 79.75M | 80.46M |
| Stockholders Equity | 0.00 | 340.83M | 410.34M | 430.67M | 364.43M | 380.53M |
Cash Flow | ||||||
| Free Cash Flow | -62.87M | -53.22K | 23.58M | 131.28M | -111.11M | -83.50M |
| Operating Cash Flow | -56.78M | -49.02K | 27.37M | 141.58M | -47.20M | -35.38M |
| Investing Cash Flow | -9.48M | -6.81K | -39.03M | 66.15M | 21.09M | -5.50M |
| Financing Cash Flow | -25.00M | -16.94K | -4.18M | -3.02M | -3.83M | -2.82M |
Orasure Technologies Technical Analysis
Neutral
3.97
Price Trends
4.16
Negative
3.62
Positive
3.14
Positive
Market Momentum
-0.01
Negative
46.26
Neutral
70.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Neutral. The current price of 3.97 is below the 20-day moving average (MA) of 4.04, below the 50-day MA of 4.16, and above the 200-day MA of 3.14, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 46.26 is Neutral, neither overbought nor oversold. The STOCH value of 70.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OSUR.
Orasure Technologies Risk Analysis
Orasure Technologies disclosed 66 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orasure Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $224.54M | 21.90 | 8.74% | 1.84% | -7.00% | ― | |
69 Neutral | $184.46M | 24.03 | 14.81% | ― | 3.50% | 157.81% | |
67 Neutral | $311.28M | -8.69 | -246.44% | ― | 17.41% | -189.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $278.84M | -3.89 | -21.50% | ― | -30.08% | -143.79% | |
47 Neutral | $123.40M | -5.16 | -153.21% | ― | 13.40% | 20.97% |
* Healthcare Sector Average
OSUR
Orasure Technologies
4.00
1.26
45.72%
INFU
InfuSystem Holdings
11.87
4.35
57.85%
STXS
Stereotaxis
1.36
-0.83
-37.90%
UTMD
Utah Medical Products
69.97
15.36
28.13%
MBOT
Microbot Medical
1.80
-1.12
-38.36%
SMTI
Sanara MedTech
34.09
9.73
39.94%
Orasure Technologies Corporate Events
Business Operations and StrategyProduct-Related Announcements
OraSure Wins FDA Clearance for At-Home STI Collection
Positive
Jun 11, 2026
On June 11, 2026, OraSure Technologies, Inc. announced that the U.S. FDA cleared its Colli-Pee Dx Urine Collection Kit from subsidiary DNA Genotek Inc. for use with Roche molecular tests for four sexually transmitted infections on Roche’s co...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
OraSure Technologies Investors Approve Expanded Stock Plan, Governance Changes
Positive
Jun 3, 2026
At its June 3, 2026 annual meeting, OraSure Technologies’ stockholders approved an amendment and restatement of the company’s 2000 Stock Award Plan, increasing the pool of common shares available for equity grants by 5,000,000, a move ...
Business Operations and StrategyFinancial Disclosures
OraSure Technologies Reports First-Quarter 2026 Financial Results
Negative
May 6, 2026
On May 6, 2026, OraSure Technologies reported first-quarter 2026 results, posting total net revenues of $27.9 million, slightly below the prior year as COVID-19 and risk assessment testing revenues declined, but with core business sales essentiall...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.